IRIDEX (NASDAQ:IRIX) Stock: Insider Shih-Yao David Lin Buys 39,937 Shares

Posted by Stanley Muller on Oct 9th, 2026

IRIDEX Corporation (NASDAQ:IRIX – Get Free Report) major shareholder Shih-Yao David Lin bought 39,937 shares of the stock in a transaction on Thursday, May 15th. The shares were bought at an average price of $1.00 per share, with a total value of $39,937.00. Following the acquisition, the insider owned 338,285 shares of the company’s stock, valued at $338,285. This trade represents a 13.39% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

IRIDEX Trading Up 2.2%

Shares of NASDAQ IRIX opened at $0.90 on Friday. IRIDEX Corporation has a 12-month low of $0.61 and a 12-month high of $1.65. The stock’s fifty day simple moving average is $0.73 and its two-hundred day simple moving average is $0.95. The stock has a market capitalization of $15.78 million, a PE ratio of -4.49 and a beta of 0.67.

IRIDEX (NASDAQ:IRIX – Get Free Report) last released its quarterly earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.06). The firm had revenue of $12.57 million during the quarter, compared to analysts’ expectations of $13.59 million. On average, equities analysts predict that IRIDEX Corporation will post -0.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 2nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, IRIDEX currently has an average rating of “Hold” and an average price target of $3.00.

Check Out Our Latest Analysis on IRIX

IRIDEX News Summary

Here are the key news stories impacting IRIDEX this week:

Positive Sentiment: Lin reported another purchase of 10,000 IRIX shares at an average price of $1.05, worth $10,500. The transaction increased his direct holdings to 735,561 shares. IRIDEX major shareholder buys 10,000 shares
Positive Sentiment: SEC disclosures show a sustained accumulation campaign by Lin, including purchases of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00, along with numerous other transactions. Repeated buying by a major shareholder may signal confidence in IRIDEX’s longer-term prospects and can support momentum in a low-market-cap stock. IRIDEX major shareholder buys 50,000 shares
Positive Sentiment: Several institutional investors also increased positions, including Perkins Capital Management, Thompson Davis, and Renaissance Technologies. Institutions own approximately 20.1% of IRIDEX’s shares, providing additional ownership support, though their disclosed positions remain relatively small in dollar terms.
Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down pause. The halt underscores unusually high volatility and the possibility of sharp price reversals when trading resumes.
Neutral Sentiment: Analyst sentiment remains mixed: one analyst rates the stock Buy and another Sell, resulting in a consensus Hold rating. The reported consensus price target is $3.00, but the limited coverage reduces its reliability.
Negative Sentiment: IRIDEX’s latest reported quarter remains a fundamental concern. The company posted a $0.07-per-share loss versus a $0.01 expected loss and revenue of $12.57 million versus the $13.59 million consensus estimate. Analysts expect a full-year loss of approximately $0.12 per share.

Hedge Funds Weigh In On IRIDEX

A number of large investors have recently made changes to their positions in the business. Perkins Capital Management Inc. boosted its position in shares of IRIDEX by 33.9% in the 1st quarter. Perkins Capital Management Inc. now owns 55,300 shares of the medical equipment provider’s stock worth $56,000 after purchasing an additional 14,000 shares in the last quarter. Thompson Davis & CO. Inc. boosted its holdings in IRIDEX by 66.5% in the first quarter. Thompson Davis & CO. Inc. now owns 47,444 shares of the medical equipment provider’s stock worth $48,000 after acquiring an additional 18,944 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of IRIDEX by 6.7% during the first quarter. Renaissance Technologies LLC now owns 396,627 shares of the medical equipment provider’s stock worth $401,000 after acquiring an additional 25,067 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of IRIDEX during the second quarter valued at about $29,000. Finally, Diversify Wealth Management LLC acquired a new position in shares of IRIDEX during the first quarter valued at about $35,000. 20.10% of the stock is owned by institutional investors and hedge funds.

About IRIDEX

(Get Free Report)

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.